<DOC>
	<DOCNO>NCT00632723</DOCNO>
	<brief_summary>This phase II trial ass whether IRESSA™ ( gefitinib ) anti-tumour efficacy patient breast cancer . The trial propose enter 27 patient acquire resistance tamoxifen 27 patient ER negative tumour . However two type patient recruitment stop 14 patient enter order confirm IRESSA™ ( gefitinib ) anti-tumour efficacy . If patient 14 group show clinical benefit ( ie objective response ( CR PR ) stable disease ( SD ) least 24 week ) clinical benefit rate &gt; 20 % rule &gt; 95 % certainty . If one objective response stable disease ( &gt; 24 week ) see first 14 patient recruit group recruitment group recommence total 27 patient . If 14 patient enter arm 14 patient available final analysis toxicity/safety tolerability profile therapy acceptable documented clinical benefit see patient , enrolment additional patient beyond initial 14 may make base overall clinical assessment .</brief_summary>
	<brief_title>IRESSA™ ( Gefitinib ) Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>histological cytological confirmation breast cancer either primary tumour patient unfit decline surgery advance ( locally metastatic ) disease acquire resistance tamoxifen ER negative tumour least one measurable assessable lesion WHO performance status 0 2 life expectancy 12 week one previous chemotherapy regimen advance disease prior anthracycline chemotherapy ( &gt; 250 mg/m2 adriamycin ) radiotherapy complete within 14 day prior Day 1 treatment incomplete heal prior oncologic major surgery sign neurological symptom consistent spinal cord compression evidence clinically active interstitial lung disease ( patient chronic stable</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>oestrogen receptor</keyword>
	<keyword>ER negative tumour</keyword>
	<keyword>epidermal growth factor receptor ( EGFR )</keyword>
</DOC>